Repurposing drugs to target nonalcoholic steatohepatitis.
Ontology highlight
ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) is a complex disorder that has evolved in recent years as the leading global cause of chronic liver damage. The main obstacle to better disease management pertains to the lack of approved pharmacological interventions for the treatment of nonalcoholic steatohepatitis (NASH) and NASH-fibrosis-the severe histological forms. Over the past decade, tremendous advances have been made in NAFLD research, resulting in the discovery of disease mechanisms and novel therapeutic targets. Hence, a large number of pharmacological agents are currently being tested for safety and efficacy. These drugs are in the initial pharmacological phases (phase 1 and 2), which involve testing tolerability, therapeutic action, and pharmacological issues. It is thus reasonable to
SUBMITTER: Sookoian S
PROVIDER: S-EPMC6478618 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA